Evidence map›Paper›PMID 11021753›Full record

ArticleLeukemia2000

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.

C T Jordan, D Upchurch, S J Szilvassy, M L Guzman, D S Howard, A L Pettigrew, T Meyerrose, R Rossi, B Grimes, D A Rizzieri and 2 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 393 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
393citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02661022 phase1 / phase2terminatednot on this mapstarted 2016, after this paper: background citation

A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

TypeinterventionalSponsorStemline Therapeutics, Inc.Ran2016 to 2019Enrolled9ConditionsMultiple MyelomaArmsSL-401 7 µg/kg/day, SL-401 9 µg/kg/day
NCT06414681 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation

An Open Label Pilot Trial of the Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2026Enrolled20ConditionsMyelofibrosis，MFArmsTagraxofusp, Pacritinib
3 · Its place in the literature

Who cites it

393 citing papers in PubMed, 1 synthesis or guideline pooled it, 810 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Recent advances in CAR T and CAR NK cell therapy for AML.International journal of hematology · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

333 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

C T JordanDivision of Hematology/Oncology, University of Kentucky Medical Center, Lexington 40536-0093, USA.
D Upchurch
S J Szilvassy
M L Guzman
D S Howard
A L Pettigrew
T Meyerrose
R Rossi
B Grimes
D A Rizzieri
S M Luger
G L Phillips
University of Kentucky · USMarkey Cancer Center · USDuke University · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies suggest that the population of malignant cells found in human acute myelogenous leukemia (AML) arises from a rare population of leukemic stem cells (LSCs). LSCs have been documented for nearly all AML subtypes and have been phenotypically described as CD34+/CD38- or CD34+/HLA-DR-. Given the potentially critical role of these primitive cells in perpetuating leukemic disease, we sought to further investigate their molecular and cellular characteristics. Flow cytometric studies using primary AML tissue showed that the interleukin-3 receptor alpha chain (IL-3Ralpha or CD123) was strongly expressed in CD34+/CD38- cells (98 +/- 2% positive) from 16 of 18 primary specimens. Conversely, normal bone marrow derived CD34+/CD38- cells showed virtually no detectable expression of the CD123 antigen. To assess the functional role of IL-3Ralpha positive cells, purified CD34+/CD123+ leukemia cells were transplanted into immune deficient NOD/SCID mice. These experiments showed that CD123+ cells were competent to establish and maintain leukemic populations in vivo. To begin to elucidate a biological role for CD123 in leukemia, primary AML samples were analyzed with respect to signal transduction activity in the MAPK, Akt, and Stat5 pathways. Phosphorylation was not detected in response to IL-3 stimulation, thereby suggesting CD123 is not active in conventional IL-3-mediated signaling. Collectively, these data indicate that CD123 represents a unique marker for primitive leukemic stem cells. Given the strong expression of this receptor on LSCs, we propose that targeting of CD123 may be a promising strategy for the preferential ablation of AML cells.

Indexed as

AnimalsHumansImmunophenotypingLeukemia, Myeloid, AcuteMiceMice, Inbred NODMice, SCIDReceptors, Interleukin-3Stem CellsReceptors, Interleukin-3

Identifiers

PMID11021753
OpenAlexW2070387456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.